1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Primary Biliary Cirrhosis - Pipeline Review, H1 2017

Primary Biliary Cirrhosis - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 95 pages

Primary Biliary Cirrhosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis – Pipeline Review, H1 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Primary Biliary Cirrhosis - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Biliary Cirrhosis - Overview
Primary Biliary Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Biliary Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Eisai Co Ltd
Enanta Pharmaceuticals Inc
Genextra Spa
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
MediGene AG
NGM Biopharmaceuticals Inc
Novartis AG
Retrophin Inc
Shire Plc
Virobay Inc
Primary Biliary Cirrhosis - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
E-6011 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
EDP-305 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
etrasimod arginine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
FFP-104 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GKT-831 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GS-9674 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
LJN-452 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
RhuDex - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
seladelpar - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ursodiol - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Primary Biliary Cirrhosis - Dormant Projects
Primary Biliary Cirrhosis - Product Development Milestones
Featured News and Press Releases
Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
Oct 20, 2016: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting
Oct 20, 2016: CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines Designation for the Treatment of Primary Biliary Cholangitis
Oct 05, 2016: CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC
May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody
Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015
Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017
Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017
Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017
Primary Biliary Cirrhosis - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dermatology Therapeutics Drug Development Pipeline Review, 2016

Dermatology Therapeutics Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Dermatology Therapeutics Drug Development Pipeline Review, 2016 Summary Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population ...

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global ...

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Intercellular Adhesion Molecule 1 (Major Group Rhinovirus ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.